Technical Analysis for CLVS - Clovis Oncology, Inc.

Grade Last Price % Change Price Change
grade F 24.24 -0.53% -0.13
CLVS closed down 0.53 percent on Wednesday, February 20, 2019, on 59 percent of normal volume.

Earnings due: Feb 26

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical CLVS trend table...

Date Alert Name Type % Chg
Feb 20 New Downtrend Bearish 0.00%
Feb 20 Bollinger Band Squeeze Range Contraction 0.00%
Feb 19 Fell Below 20 DMA Bearish -0.53%
Feb 19 Bollinger Band Squeeze Range Contraction -0.53%
Feb 15 Pocket Pivot Bullish Swing Setup -4.90%
Feb 15 Bollinger Band Squeeze Range Contraction -4.90%
Feb 15 BB Squeeze Started Range Contraction -4.90%
Feb 14 20 DMA Support Bullish -4.83%
Feb 14 180 Bullish Setup Bullish Swing Setup -4.83%
Feb 12 1,2,3 Pullback Bullish Bullish Swing Setup -3.77%

Older signals for CLVS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has two clinical development programs and one drug discovery program underway. Its clinical development programs include CO-1686, which is Phase I/II study is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is the subject of a development program for the treatment of non-small cell lung cancer in patients with activating EGFR mutations, as well as the primary resistance mutation, T790M; and rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase that is being explored in Phase I/II clinical trials for ovarian and breast cancer patients with BRCA mutations and other DNA repair deficiencies. The company's drug discovery program includes its mutant cKit inhibitor discovery program targeting the resistance mutations that occur in the majority of gastrointestinal stromal tumor patients and result in disease progression. It has license agreements with Avila Therapeutics, Inc. and Pfizer Inc.; a drug discovery collaboration agreement with Array BioPharma Inc.; and collaborations with Roche Molecular Systems and Foundation Medicine, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Biopharmaceutical Chemical Compounds Disease Organic Compounds Drug Discovery Breast Cancer Non Small Cell Lung Cancer Lung Cancer Treatment Of Non Small Cell Lung Cancer Epidermal Growth Factor Receptor Lactams Indoles Gastrointestinal Stromal Tumor Heterocyclic Compounds
Is CLVS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 65.24
52 Week Low 11.5
Average Volume 2,303,749
200-Day Moving Average 32.0617
50-Day Moving Average 22.3542
20-Day Moving Average 24.9155
10-Day Moving Average 25.158
Average True Range 1.2466
ADX 27.02
+DI 20.442
-DI 21.6694
Chandelier Exit (Long, 3 ATRs ) 22.8302
Chandelier Exit (Short, 3 ATRs ) 25.3998
Upper Bollinger Band 26.2875
Lower Bollinger Band 23.5435
Percent B (%b) 0.25
BandWidth 11.013225
MACD Line 0.6933
MACD Signal Line 0.9713
MACD Histogram -0.278
Fundamentals Value
Market Cap 1.18 Billion
Num Shares 48.8 Million
EPS -8.90
Price-to-Earnings (P/E) Ratio -2.72
Price-to-Sales 167.14
Price-to-Book 10.56
PEG Ratio 0.12
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 26.09
Resistance 3 (R3) 26.10 25.50 25.78
Resistance 2 (R2) 25.50 25.03 25.49 25.67
Resistance 1 (R1) 24.87 24.74 24.57 24.86 25.57
Pivot Point 24.27 24.27 24.12 24.26 24.27
Support 1 (S1) 23.64 23.80 23.34 23.63 22.91
Support 2 (S2) 23.04 23.51 23.03 22.81
Support 3 (S3) 22.41 23.04 22.70
Support 4 (S4) 22.40